BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 27631211)

  • 21. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial.
    Breugom AJ; van Gijn W; Muller EW; Berglund Å; van den Broek CBM; Fokstuen T; Gelderblom H; Kapiteijn E; Leer JWH; Marijnen CAM; Martijn H; Meershoek-Klein Kranenbarg E; Nagtegaal ID; Påhlman L; Punt CJA; Putter H; Roodvoets AGH; Rutten HJT; Steup WH; Glimelius B; van de Velde CJH
    Ann Oncol; 2015 Apr; 26(4):696-701. PubMed ID: 25480874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Outcomes of Neoadjuvant Treatment Prior to Total Mesorectal Excision and Total Mesorectal Excision Alone in Selected Stage II/III Low and Mid Rectal Cancer.
    Kulu Y; Tarantino I; Billeter AT; Diener MK; Schmidt T; Büchler MW; Ulrich A
    Ann Surg Oncol; 2016 Jan; 23(1):106-13. PubMed ID: 26305025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.
    Markovina S; Youssef F; Roy A; Aggarwal S; Khwaja S; DeWees T; Tan B; Hunt S; Myerson RJ; Chang DT; Parikh PJ; Olsen JR
    Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):417-426. PubMed ID: 28871992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative long course chemoirradiation in a developing country for rectal carcinoma: Kuala Lumpur hospital experience.
    Lee WC; Yusof MM; Lau FN; Phua VC
    Asian Pac J Cancer Prev; 2013; 14(6):3941-4. PubMed ID: 23886211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial.
    Li Q; Luo D; Zhu J; Yang L; Liu Q; Ma Y; Liang L; Cai S; Zhang Z; Li X;
    BMC Cancer; 2019 Nov; 19(1):1117. PubMed ID: 31729964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term prognostic value of mesorectal grading after neoadjuvant chemoradiotherapy for rectal cancer.
    Madbouly KM; Hussein AM; Abdelzaher E
    Am J Surg; 2014 Sep; 208(3):332-41. PubMed ID: 24581995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncological outcomes of robotic-assisted total mesorectal excision after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
    Chen PJ; Su WC; Chang TK; Chen YC; Li CC; Yin TC; Tsai HL; Ma CJ; Huang CW; Wang JY
    Asian J Surg; 2021 Jul; 44(7):957-963. PubMed ID: 33622595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of adjuvant chemotherapy on survival and recurrence after curative rectal cancer surgery in patients who are histologically node negative after neoadjuvant chemoradiotherapy.
    Baird DLH; Denost Q; Simillis C; Pellino G; Rasheed S; Kontovounisios C; Tekkis PP; Rullier E
    Colorectal Dis; 2017 Nov; 19(11):980-986. PubMed ID: 28493401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation of progression-free survival for locally advanced rectal cancer by MRI after neoadjuvant chemoradiotherapy and total mesorectal excision].
    Zhang JX; Yang Z; Fan P; Zhang JJ; Xin L; Hou LN; Du XS; Yang XT
    Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):121-126. PubMed ID: 29502372
    [No Abstract]   [Full Text] [Related]  

  • 30. Different Impacts of Preoperative Radiotherapy and Chemoradiotherapy on Oncological Outcomes in Patients with Stages II and III Lower Rectal Cancer: A Propensity Score Analysis.
    Takiyama H; Kawai K; Ishihara S; Yasuda K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Hata K; Nozawa H; Morikawa T; Watanabe T
    Dig Surg; 2018; 35(3):212-219. PubMed ID: 28637039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.
    Akgun E; Ozkok S; Tekin M; Yoldas T; Caliskan C; Kose T; Karabulut B; Sezak M; Elmas N; Ozutemiz O
    World J Surg Oncol; 2017 Nov; 15(1):205. PubMed ID: 29166925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
    Jao SW; Chen SF; Lin YS; Chang YC; Lee TY; Wu CC; Jin JS; Nieh S
    Ann Surg Oncol; 2012 Oct; 19(11):3432-40. PubMed ID: 22739652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Local excision in rectal cancer patients with major or complete clinical response after neoadjuvant therapy: a case-matched study.
    Bushati M; Pucciarelli S; Gennaro N; Maretto I; Toppan P; Perin A; Urso EDL; Bagatella A; Spolverato G
    Int J Colorectal Dis; 2019 Dec; 34(12):2129-2136. PubMed ID: 31724079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant concurrent chemoradiotherapy in treating locally advanced rectal cancer.
    Twu CM; Wang HM; Chen JB; Chao TH; Mar HF
    J Chin Med Assoc; 2009 Apr; 72(4):179-82. PubMed ID: 19372072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changing operative strategy from abdominoperineal resection to sphincter preservation in T3 low rectal cancer after downstaging by neoadjuvant chemoradiation: a preliminary report.
    Madbouly KM; Hussein AM
    World J Surg; 2015 May; 39(5):1248-56. PubMed ID: 25561197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer.
    Cai G; Zhu J; Palmer JD; Xu Y; Hu W; Gu W; Cai S; Zhang Z
    Radiat Oncol; 2015 Feb; 10():57. PubMed ID: 25889149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association Between Incomplete Neoadjuvant Radiotherapy and Survival for Patients With Locally Advanced Rectal Cancer.
    Freischlag K; Sun Z; Adam MA; Kim J; Palta M; Czito BG; Migaly J; Mantyh CR
    JAMA Surg; 2017 Jun; 152(6):558-564. PubMed ID: 28273303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effects of neoadjuvant chemoradiotherapy on the rates of sphincter preserving surgery in lower rectal cancer and analysis of their prognostic factors].
    Wang XJ; Chi P; Lin HM; Lu XR; Huang Y; Xu ZB; Huang SH; Sun YW; Ye DX
    Zhonghua Wai Ke Za Zhi; 2016 Jun; 54(6):419-423. PubMed ID: 27938574
    [No Abstract]   [Full Text] [Related]  

  • 39. Pattern and Management of Recurrence of Mid-Low Rectal Cancer After Neoadjuvant Intensity-Modulated Radiotherapy: Single-Center Results of 687 Cases.
    Wu AW; Cai Y; Li YH; Wang L; Li ZW; Sun YS; Ji JF
    Clin Colorectal Cancer; 2018 Jun; 17(2):e307-e313. PubMed ID: 29525524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis.
    Renehan AG; Malcomson L; Emsley R; Gollins S; Maw A; Myint AS; Rooney PS; Susnerwala S; Blower A; Saunders MP; Wilson MS; Scott N; O'Dwyer ST
    Lancet Oncol; 2016 Feb; 17(2):174-183. PubMed ID: 26705854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.